Astrid Zimmermann

This inventor holds 15 USPTO granted patents and 6 published patent applications, plus 3 CIPO patents and 9 EPO patents. Top assignees: 4Sc Ag, Bayer Intellectual Property Gmbh, Merck Patent Gmbh. Active years: 2010-2026.

USPTO Granted Patents = 15 (Patent Applications = 6)

% Patents Active = 53.3

CIPO Patents = 3 (Patent Applications = 6)

EPO Patents = 9 (Patent Applications = 13)

Average Co-Inventor Count = 7.5

ph-index = 2

Forward Citations = 21(Granted Patents)

Location History:

Muhltal, DE (2012)
Constance, DE (2010 - 2016)
Mühltal, DE (2015 - 2018)
Muehltal, DE (2013 - 2022)

Company Filing History:

Bayer Intellectual Property Gmbh

Bayer Schering Pharma Ag

patents

Years Active: 2010-2026

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12616750 - COMBINATION THERAPY UTILIZING DNA ALKYLATING AGENTS AND ATR INHIBITORS (2026-05-05),

2. 12227577 - Combination of a PD-1 antagonist, an ATR inhibitor and a platinating agent for the treatment of cancer (2025-02-18),

3. 11246929 - Combination of a protein kinase inhibitor and an additional chemotherapeutic agent (2022-02-15),

4. 9908880 - Substituted imidazoquinolines (2018-03-06),

5. 9446040 - Substituted imidazoquinolines (2016-09-20),

6. 9387204 - Fused bicyclic imidazoles (2016-07-12),

7. 9073913 - Substituted imidazoquinolines (2015-07-07),

8. 8815855 - N-sulphonylpyrroles and their use as histone deacetylase inhibitors (2014-08-26),

9. 8614218 - Fused bicyclic pyrimidines (2013-12-24),

10. 8592591 - Fused bicyclic imidazoles (2013-11-26),

11. 8530493 - Indolopyridines as Eg5 kinesin modulators (2013-09-10),

12. 8440830 - Tetrahydro-fused pyridines as histone deacetylase inhibitors (2013-05-14),

13. 8273890 - Thiophene-imidazopyridines (2012-09-25),

14. 7776864 - Fused bicyclic pyrimidines (2010-08-17),

15. 7666868 - N-sulphonylpyrroles and their use as histone deacetylase inhibitors (2010-02-23),

Title: Astrid Zimmermann: Innovator in Cancer Treatment

Introduction

Astrid Zimmermann is a prominent inventor based in Constance, Germany. She has made significant contributions to the field of cancer treatment through her innovative research and development of combination therapies. With a total of 15 patents to her name, Zimmermann is recognized for her dedication to improving therapeutic options for patients.

Latest Patents

Among her latest patents is a groundbreaking invention titled "Combination of a PD-1 antagonist, an ATR inhibitor and a platinating agent for the treatment of cancer." This invention focuses on combination therapies that are particularly useful in treating cancer. It highlights the therapeutic potential of combining a PD-1 antagonist, an ATR inhibitor, and a platinating agent. Another notable patent is "Combination of a protein kinase inhibitor and an additional chemotherapeutic agent," which also addresses combination therapy for cancer treatment.

Career Highlights

Throughout her career, Astrid Zimmermann has worked with notable companies such as 4SC AG and Bayer Intellectual Property GmbH. Her work in these organizations has allowed her to advance her research and contribute to the development of innovative cancer therapies.

Collaborations

Zimmermann has collaborated with esteemed colleagues, including Volker Gekeler and Thomas Maier. These partnerships have played a crucial role in her research endeavors and have facilitated the exchange of ideas and expertise in the field.

Conclusion

Astrid Zimmermann's contributions to cancer treatment through her innovative patents and collaborations underscore her importance in the field of medical research. Her work continues to inspire advancements in therapeutic options for patients battling cancer.